The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

London stocks had pared gains by midday on Friday, with GSK under the cosh. The FTSE 100 was flat at 8,971.33, having ...

London's main stock indexes rose on Friday, with the blue-chip index hovering near record highs, aided by a slew of positive ...

European and Asian stocks markets closed out the week broadly higher Friday following Wall Street's latest record highs ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

Euro US Dollar, British Pound US Dollar, US Dollar Japanese Yen, FTSE 100. Read 's Market Analysis on Investing.com ...

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

The jet maker said it has agreed to sell 12 of the aircraft to the airline, with options for six more. The British pharmaceutical company said combinations for its Blenrep drug were evaluated in ...